ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 483

Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience

Francesca De Nard1, Vittorio Grosso2, Monica Todoerti3, Carlomaurizio Montecucco4 and Roberto Caporali5, 1Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 2Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, 3Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 4Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, 5Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Abatacept, Biologic drugs, Hepatitis, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis reactivation under anti-TNF agents has been well described, experience with drugs as tocilizumab (TCZ) and abatacept (ABA) is still limited (2). Aim of this study is to retrospectively assess the risk of HBV reactivation in real-life RA patients treated with ABA and TCZ.

Methods

RA patients with a past HBV infection history (‘chronic inactive carriers’ with HBsAg+ and undetectable or <2,000 IU/mL viral load + normal liver function tests (LFT) and ‘occult carriers' with only HBcAb+) and treated with ABA or TCZ, have been retrospectively analyzed for the risk of ‘viral re-activation' (rise in viral load≥1 log10 IU/mL compared with baseline values, or detection of previously undetected serum HBV-DNA) and/or ‘viral hepatitis B' (increase in LFT and serum HBV-DNA, necroinflammation and/or fibrosis in liver biopsy)  by regularly detecting HBsAg, HBV-DNA, LFT throughout follow-up.

Results

Out of a total of 125 RA patients, 17 (13,6%) were HbcAb+: 16 occult carriers (8 treated with ABA+8 treated with TCZ), and 1 chronic inactive carrier treated with ABA. Patients have been followed for a median time (IQR) of 1.2 (0.7-1.5) years. They were previously treated with a median (IQR) number of 2 (1-3) synthetic DMARDs (sDMARDs) and 0 (0-1) bDMARDs. The mean age (sd) was 54.7 (13.8) years, the median disease duration was 5.8 (1.8-7.6) years. Most patients were treated with concomitant methotrexate (8/9 in the ABA group, 5/8 in the TCZ group) and corticosteroids. In the ABA group, 1 patient with chronic HCV co-infection (HCV-RNA+) started lamivudine, due to LFT elevation (<2-fold ULN) occurring 2 months after ABA initiation; amelioration of LFT along with undetectable viral load occurred throughout 12 months of follow-up. 2 patients (1 occult carrier and 1 chronic inactive carrier) underwent lamivudine before ABA with no HBV-related adverse events; among the other 6 ABA patients not receiving lamivudine only 1 experienced a temporary positivization of viral load (85 UI/mL) without LFT elevation at 12 months of follow-up: spontaneous negativization of viral load was registered at 18 months. In the TCZ group, no patient received lamivudine with no HBV reactivation.

Conclusion

Despite limited to few patients and short follow-up, the use of ABA and TCZ in RA patients with past history of HBV infection seems relatively safe. However, periodic monitoring of liver function tests and viral load is mandatory. According to scientific literature, viral prophylaxis might be considered mainly in patients undergoing ABA. Further data are needed to clarify long-term safety issues.

References

(1) Vassillopoulos D, et al. Nat Rev Rheumatol 2012.

(2) Kim PS, et al. Arthritis Care Res 2012.

Table 1. Characteristics of patients with RA and past HBV infection treated with ABA and TCZ.

 

 

N of patients

TCZ group

 

8

 

ABA group

 

9

TOT

 

 17

Sex (M/F)

2/6

 

2/7

4/13

Age, mean±SD (ys)

49.5±8.4

 

59.2±16.3

54,7±13,8

Disease duration, median (IQR) (ys)

4,7 (1,7-7,5)

 

5,8 (2,2-7,9)

5,8 (1,8-7,6)

Duration of follow-up, median (IQR) (ys)

1,2(0,9-1,5)

 

1,2 (0,7-1,5)

1,2 (0,7-1,5)

Number of previous sDMARDs, median (IQR)

2 (1-3)

 

2 (1-3)

2 (1-3)

Number of previous bDMARDs,  median (IQR)

1 (0-1)

 

0 (0-2)

0 (0-1)

Co-treatment: steroids

7

 

8

 15

Co-treatment: methotrexate

5

 

8

 13

Chronic inactive infection

0

 

1

 1

Occult carrier

8

 

8

 16

Antiviral prophylaxis

0

3

 3

 


Disclosure:

F. De Nard,
None;

V. Grosso,
None;

M. Todoerti,
None;

C. Montecucco,
None;

R. Caporali,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-hbv-reactivation-in-rheumatoid-arthritis-patients-undergoing-treatment-with-newer-biological-dmards-tocilizumab-and-abatacept-a-single-center-real-life-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology